Nothing Special   »   [go: up one dir, main page]

Dubal et al., 2015 - Google Patents

Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice

Dubal et al., 2015

View PDF
Document ID
4182097877443516843
Author
Dubal D
Zhu L
Sanchez P
Worden K
Broestl L
Johnson E
Ho K
Yu G
Kim D
Betourne A
Kuro-o M
Masliah E
Abraham C
Mucke L
Publication year
Publication venue
Journal of Neuroscience

External Links

Snippet

Aging is the principal demographic risk factor for Alzheimer disease (AD), the most common neurodegenerative disorder. Klotho is a key modulator of the aging process and, when overexpressed, extends mammalian lifespan, increases synaptic plasticity, and enhances …
Continue reading at www.jneurosci.org (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Dubal et al. Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice
Cline et al. The amyloid-β oligomer hypothesis: beginning of the third decade
Chang et al. Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies
Wang et al. Deficiency in BDNF/TrkB neurotrophic activity stimulates δ-secretase by upregulating C/EBPβ in Alzheimer’s disease
Gulisano et al. Role of amyloid-β and tau proteins in Alzheimer’s disease: confuting the amyloid cascade
Sakae et al. ABCA7 deficiency accelerates amyloid-β generation and Alzheimer's neuronal pathology
Haure-Mirande et al. Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer’s pathology
Han et al. Mitophagy regulates integrity of mitochondria at synapses and is critical for synaptic maintenance
Lian et al. Signaling pathways regulating neuron–glia interaction and their implications in Alzheimer's disease
Shi et al. Complement C3-deficient mice fail to display age-related hippocampal decline
Andrews-Zwilling et al. Apolipoprotein E4 causes age-and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice
Stephan et al. A dramatic increase of C1q protein in the CNS during normal aging
Billings et al. Learning decreases Aβ* 56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice
Shilling et al. Suppression of InsP3 receptor-mediated Ca2+ signaling alleviates mutant presenilin-linked familial Alzheimer's disease pathogenesis
Sato et al. Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1
Chakravarthy et al. Amyloid-β peptides stimulate the expression of the p75 NTR neurotrophin receptor in SHSY5Y human neuroblastoma cells and AD transgenic mice
Roberts et al. A brain proteomic signature of incipient Alzheimer’s disease in young APOE ε4 carriers identifies novel drug targets
Cudaback et al. APOE genotype‐dependent modulation of astrocyte chemokine CCL3 production
You et al. Tau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy
Chhimpa et al. The novel role of mitochondrial citrate synthase and citrate in the pathophysiology of Alzheimer’s disease
Minakawa et al. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation
Jeong et al. Broad activation of the Parkin pathway induces synaptic mitochondrial deficits in early tauopathy
Guan et al. As a potential therapeutic target, C1q induces synapse loss via inflammasome-activating apoptotic and mitochondria impairment mechanisms in Alzheimer’s disease
Zhang et al. Tau induces inflammasome activation and microgliosis through acetylating NLRP3
Hu et al. A novel LGI1 mutation causing autosomal dominant lateral temporal lobe epilepsy confirmed by a precise knock‐in mouse model